Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil once daily for men with erectile dysfunction and benign prostatic hyperplasia symptoms
2008-004337-25Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tadalafil in benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change from baseline to end of therapy in Total International Prostate Symptom Score and Change from baseline to end of therapy in International Index of Erectile Function Erectile Function Domain score. Started Jan 2009; status: completed.
02
Drugs
tadalafil
03
Conditions
benign prostatic hyperplasia (BPH)erectile dysfunction (ED)
Beyond the preview
Go deeper on 2008-004337-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004337-25.